Syntegon delivers strong growth and margin expansion in Q3 2025 with accelerating pharma momentum and profitability gains across all segments

Syntegon Group, a leading strategic partner to the pharmaceutical, biotech, and food industries, continued its strong growth and margin-improvement momentum in the third quarter of 2025, building on a successful first half of the year.

Group sales in the third quarter increased by 19% versus prior year to €448m, supported by strong underlying organic growth rate of 15%. The main contributor was Syntegon’s Pharma business, which delivered sales growth of 32%, thereof 20% organic growth. This excellent performance was driven by continued customer demand and new project wins, following the successful introduction of innovative technologies aligned with Syntegon’s growth strategy launched in 2024.

Adjusted EBITDA for the quarter increased by 37% to €75m, resulting in an EBITDA margin of 16.7%, up 230 bps versus prior year. The margin expansion was driven by higher volume leverage, the continued execution of margin-enhancing operational excellence initiatives, and a strategic focus on higher-margin business segments.

New solutions drive growth and customer interest

Continued innovation and new technologies contributed significantly to Syntegon’s third-quarter growth. Integrated vial line growth accelerated, enabled by the successful integration of Telstar, acquired in Q4 2024. As part of Syntegon, Telstar delivered a substantial margin improvement and attractive growth in its core freeze dryer business. The company also recorded strong order intake in its RTU syringe business. SynTiso, the industry’s first gloveless, high-speed isolator-integrated fill/finish line, received very positive market reception. In the Food segment, growth continued to be driven by the new SVX platform, which contributed to higher margins through its modular and scalable design.

Torsten Türling, CEO of Syntegon, said: Our growth and value-creation strategy is delivering measurable impact and underscores the trust our customers place in Syntegon as their strategic lifecycle partner for mission-critical technologies. With our global footprint and our innovative technologies, we are exceptionally well positioned to capture the long-term growth opportunities in our customer’s industries.

Strong nine-month results with double-digit growth and enhanced profitability

Group sales for the first nine months increased by 14% to €1,272m, incl. 11% organic growth. Adjusted EBITDA rose by 40% to €202m, corresponding to a margin of 15.9%, up by 300 bps versus prior year. Free cash flow also developed positively, improving by 31% to €102m over the same period. This performance was supported by disciplined working capital management and targeted capex investments of 2.6% of sales.

Potential headwinds from global trade developments, particularly U.S. tariffs, are being mitigated through countermeasures, Syntegon’s globally balanced supply chain, and long-term customer partnerships. The company expects only minimal impact in 2025. In addition, the expansion of production capacities in the U.S. pharma sector is creating further opportunities for Syntegon.

Eros Carletti, CFO of Syntegon, said: Our strong Q3 and year-to-date results underline the financial resilience of our business. Higher volumes in attractive margin segments, combined with seamless project execution and tight cost controls, have enabled us to achieve another quarter of robust profitability. Our solid cash flow further reinforces our financial strength and provides us with the flexibility to continue investing in strategic priorities. We remain committed to driving margin expansion and maintaining a strong financial foundation.

Outlook full year 2025

With strong growth, consistent margin improvement, and a record-high order backlog, Syntegon remains well positioned to deliver another record year.